The treatment landscape for breast cancer was positively impacted by the molecular classification of subtypes initially proposed by Professor Charles Perou in 2000: luminal (HR+), basal (HR− and HER-2−), and HER-2 overexpression (HR− and HER-2+). This evidence concerns the gene ERBB2 and breast carcinoma.